3. (((fatty or fat or steato*) adj3 (liver* or hepat*)) or steatohepat* or (visceral adj2 steato*)).ti,ab
|
|
- Jane Leonard
- 5 years ago
- Views:
Transcription
1 Search strategy for MEDLINE Steatosis: 1. fatty liver/ 2. non-alcoholic fatty liver disease/ 3. (((fatty or fat or steato*) adj3 (liver* or hepat*)) or steatohepat* or (visceral adj2 steato*)).ti,ab 4. (nafl* or nash).ti,ab. 5. or/ letter/ 7. editorial/ 8. news/ 9. exp historical article/ 10. anecdotes as topic/ 11. comment/ 12. case report/ 13. (letter or comment*).ti. 14. or/ randomized controlled trial/ or random*.ti,ab not animals/ not humans/ 18. exp animals, laboratory/ 19. exp animal experimentation/ 20. exp models, animal/ 21. exp rodentia/ 22. (rat or rats or mouse or mice).ti. 23. or/ not
2 26. limit 24 to English language 27. alanine transaminase/ 28. aspartate aminotransferases/ 29. gamma-glutamyltransferase/ 30. (test* or measure* or level* or ratio*).ti,ab. 31. or/ and ((alanine transaminase* or alt or aspartate aminotransferase* or ast or gamma glutamyltransferase* or gamma gt or gammagt or ggt) adj4 (test* or measure* or level* or ratio*)).ti,ab. 34. (fatty liver ind* or fli).ti,ab. 35. (steatotest or steato test).ti,ab. 36. liver fat scor*.ti,ab. 37. ultrasonography/ or exp ultrasonography, doppler/ 38. (ultrasound* or ultrason* or sonograph* or echograph*).ti,ab. 39. magnetic resonance imaging/ 40. magnetic resonance spectroscopy/ 41. (mri or mrs or ((magnetic or mr) adj2 (imag* or spectroscop*))).ti,ab. 42. controlled attenuation parameter.ti,ab. 43. elasticity imaging techniques/ 44. alanine transaminase/ 45. or/ and exp "sensitivity and specificity"/ 48. (sensitivity or specificity).ti,ab. 49. ((pre test or pretest or post test) adj probability).ti,ab. 50. (predictive value* or ppv or npv).ti,ab. 51. likelihood ratio*.ti,ab.
3 52. likelihood function/ 53. (roc curve* or auc).ti,ab. 54. (diagnos* adj3 (performance* or accurac* or utilit* or value* or efficien* or effectiveness)).ti,ab. 55. gold standard.ab. 56. or/ and limit 57 to yr="2015 -Current" Fibrosis: 1. fatty liver/ 2. non-alcoholic fatty liver disease/ 3. (((fatty or fat or steato*) adj3 (liver* or hepat*)) or steatohepat* or (visceral adj2 steato*)).ti,ab. 4. (nafl* or nash).ti,ab. 5. or/ letter/ 7. editorial/ 8. news/ 9. exp historical article/ 10. anecdotes as topic/ 11. comment/ 12. case report/ 13. (letter or comment*).ti. 14. or/ randomized controlled trial/ or random*.ti,ab not animals/ not humans/ 18. exp animals, laboratory/ 19. exp animal experimentation/
4 20. exp models, animal/ 21. exp rodentia/ 22. (rat or rats or mouse or mice).ti. 23. or/ not limit 24 to english language 26. biological markers/ 27. alanine transaminase/ 28. exp aspartate aminotransferases/ 29. keratin-18/ 30. ferritin/ 31. or/ (test* or measure* or level* or diagnos* or ratio or score*).ti,ab and (fibro test* or fibro-test* or fibrometer or fibroscan or fib4 or fib-4).ti,ab. 35. ((nafld or bard or ferritin* or fibrosis) adj4 (test* or measure* or level* or ratio or score*)).ti,ab. 36. ((glutamic-pyruvic transaminase or glutamic-oxaloacetic transaminase or sgot or sgpt or alt or ast) adj4 (test* or measure* or level* or ratio or score*)).ti,ab. 37. (aspartate adj2 (aminotransferase or apoaminotransferase or transaminase) adj4 (test* or measure* or level* or ratio or score*)).ti,ab. 38. (alanine adj2 (aminotransferase or transaminase) adj4 (test* or measure* or level* or ratio or score*)).ti,ab. 39. ((ast-to-platelet ratio index or apri or elf or enhanced liver fibrosis or nash) adj4 (test* or measure* or level* or score*)).ti,ab. 40. ((biomarker* or marker*) adj4 (test* or measure* or level* or ratio or score*)).ti,ab. 41. exp magnetic resonance spectroscopy/ 42. exp diffusion magnetic resonance imaging/ 43. (elastogra* or sonoelastogra* or elasticity imag* or sheer wave).ti,ab. 44. (acoustic radiation force impulse or arfi).ti,ab.
5 45. ((diffusion or weighted) adj2 (imag* or mri)).ti,ab. 46. (mrs or ((nmr or magnetic or mr) adj2 spectroscop*)).ti,ab. 47. or/ and exp "sensitivity and specificity"/ 50. (sensitivity or specificity).ti,ab. 51. ((pre test or pretest or post test) adj probability).ti,ab. 52. (predictive value* or ppv or npv).ti,ab. 53. likelihood ratio*.ti,ab. 54. likelihood function/ 55. (roc curve* or auc).ti,ab. 56. (diagnos* adj3 (performance* or accurac* or utilit* or value* or efficien* or effectiveness)).ti,ab. 57. gold standard.ab. 58. or/ and limit 59 to yr="2015 -Current" Search strategy for EMBASE Steatosis 1. nonalcoholic fatty liver/ 2. (((fatty or fat or steato*) adj3 (liver* or hepat*)) or steatohepat* or (visceral adj2 steato*)).ti,ab. 3. (nafl* or nash).ti,ab. 4. or/ letter.pt. or letter/ 6. note.pt. 7. editorial.pt. 8. case report/ or case study/ 9. (letter or comment*).ti.
6 10. conference*.pt. 11. or/ randomized controlled trial/ or random*.ti,ab not animal/ not human/ 15. nonhuman/ 16. exp animal experiment/ 17. exp experimental animal/ 18. animal model/ 19. exp rodent/ 20. (rat or rats or mouse or mice).ti. 21. or/ not limit 22 to english language 25. *alanine aminotransferase/ 26. *aspartate aminotransferase/ 27. *gamma glutamyltransferase/ 28. or/ (test* or measure* or level* or ratio*).ti,ab and ((alanine transaminase* or alt or aspartate aminotransferase* or ast or gamma glutamyltransferase* or gamma gt or gammagt or ggt) adj4 (test* or measure* or level* or ratio*)).ti,ab. 32. (fatty liver ind* or fli).ti,ab. 33. (steatotest or steato test).ti,ab. 34. liver fat scor*.ti,ab. 35. *echography/ or *doppler echography/
7 36. (ultrasound* or ultrason* or sonograph* or echograph*).ti,ab. 37. *nuclear magnetic resonance imaging/ 38. *nuclear magnetic resonance spectroscopy/ 39. (mri or mrs or ((magnetic or mr) adj2 (imag* or spectroscop*))).ti,ab. 40. controlled attenuation parameter.ti,ab. 41. *elastography/ 42. or/ and exp "sensitivity and specificity"/ 45. (sensitivity or specificity).ti,ab. 46. ((pre test or pretest or post test) adj probability).ti,ab. 47. (predictive value* or ppv or npv).ti,ab. 48. likelihood ratio*.ti,ab. 49. likelihood function/ 50. (roc curve* or auc).ti,ab. 51. (diagnos* adj3 (performance* or accurac* or utilit* or value* or efficien* or effectiveness)).ti,ab. 52. gold standard.ab. 53. or/ and limit 54 to yr="2015 -Current" Fibrosis: 1. nonalcoholic fatty liver/ 2. (((fatty or fat or steato*) adj3 (liver* or hepat*)) or steatohepat* or (visceral adj2 steato*)).ti,ab. 3. (nafl* or nash).ti,ab. 4. or/ letter.pt. or letter/ 6. note.pt.
8 7. editorial.pt. 8. case report/ or case study/ 9. (letter or comment*).ti. 10. or/ randomized controlled trial/ or random*.ti,ab not animal/ not human/ 14. nonhuman/ 15. exp animal experiment/ 16. exp experimental animal/ 17. animal model/ 18. exp rodent/ 19. (rat or rats or mouse or mice).ti. 20. or/ not limit 21 to english language 23. biological marker/ 24. alanine aminotransferase/ 25. exp aspartate aminotransferases/ 26. cytokeratin 18/ 27. ferritin/ 28. or/ (test* or measure* or level* or diagnos* or ratio or score*).ti,ab and (fibro test* or fibro-test* or fibrometer or fibroscan or fib4 or fib-4).ti,ab. 32. ((nafld or bard or ferritin* or fibrosis) adj4 (test* or measure* or level* or ratio or score*)).ti,ab.
9 33. ((glutamic-pyruvic transaminase or glutamic-oxaloacetic transaminase or sgot or sgpt or alt or ast) adj4 (test* or measure* or level* or ratio or score*)).ti,ab. 34. (aspartate adj2 (aminotransferase or apoaminotransferase or transaminase) adj4 (test* or measure* or level* or ratio or score*)).ti,ab. 35. (alanine adj2 (aminotransferase or transaminase) adj4 (test* or measure* or level* or ratio or score*)).ti,ab. 36. ((ast-to-platelet ratio index or apri or elf or enhanced liver fibrosis or nash) adj4 (test* or measure* or level* or score*)).ti,ab. 37. ((biomarker* or marker*) adj4 (test* or measure* or level* or ratio or score*)).ti,ab. 38. exp nuclear magnetic resonance spectroscopy/ 39. exp diffusion weighted imaging/ 40. (elastogra* or sonoelastogra* or elasticity imag* or sheer wave).ti,ab. 41. (acoustic radiation force impulse or arfi).ti,ab. 42. ((diffusion or weighted) adj2 (imag* or mri)).ti,ab. 43. (mrs or ((nmr or magnetic or mr) adj2 spectroscop*)).ti,ab. 44. or/ and exp "sensitivity and specificity"/ 47. (sensitivity or specificity).ti,ab. 48. ((pre test or pretest or post test) adj probability).ti,ab. 49. (predictive value* or ppv or npv).ti,ab. 50. likelihood ratio*.ti,ab. 51. (roc curve* or auc).ti,ab. 52. (diagnos* adj2 (performance* or accurac* or utilit* or value* or efficien* or effectiveness)).ti,ab. 53. diagnostic accuracy/ 54. diagnostic test accuracy study/ 55. gold standard.ab. 56. or/ and 56
10 58. limit 57 to yr="2015 -Current" Search strategy for Cochrane library collection Steatosis: #1 [mh ^"fatty liver"] #2 MeSH descriptor: [Non-alcoholic Fatty Liver Disease] this term only #3 (((fatty or fat or steato*) near/3 (liver* or hepat*)) or steatohepat* or (visceral near/2 steato*)):ti,ab #4 (nafl* or nash):ti,ab #5 {or #1-#4} #6 [mh ^"alanine transaminase"] #7 [mh ^"aspartate aminotransferases"] #8 [mh ^gamma-glutamyltransferase] #9 {or #2-#4} #10 (test* or measure* or level* or ratio*):ti,ab #11 #5 and #6 #12 ((alanine next transaminase* or alt or aspartate next aminotransferase* or ast or gamma next glutamyltransferase* or gamma next gt or gammagt or ggt) near/4 (test* or measure* or level* or ratio*)):ti,ab #13 (fatty next liver next ind* or fli):ti,ab #14 (steatotest or steato next test):ti,ab #15 liver next fat next scor*:ti,ab #16 [mh ^ultrasonography] #17 [mh "ultrasonography, doppler"] #18 (ultrasound* or ultrason* or sonograph* or echograph):ti,ab #19 [mh ^"magnetic resonance imaging"] #20 [mh ^"magnetic resonance spectroscopy"] #21 (mri or mrs or ((magnetic or mr) near/2 (imag* or spectroscop*))):ti,ab #22 controlled attenuation parameter:ti,ab #23 [mh ^"elasticity imaging techniques"]
11 #24 {or #11-#23} #25 #4 and #24 Publication Year from 2015 to 2017 Fibrosis #1 [mh ^"fatty liver"] #2 MeSH descriptor: [Non-alcoholic Fatty Liver Disease] this term only #3 (((fatty or fat or steato*) near/3 (liver* or hepat*)) or steatohepat* or (visceral near/2 steato*)):ti,ab #4 (nafl* or nash):ti,ab #5 {or #1-#4} #6 MeSH descriptor: [Biomarkers] this term only #7 MeSH descriptor: [Alanine Transaminase] explode all trees #8 MeSH descriptor: [Keratin-18] this term only #9 MeSH descriptor: [Ferritins] this term only #10 {or #2-#6} #11 (test* or measure* or level* or ratio or diagnos* or score*):ti,ab #12 #7 and #8 #13 (fibro test* or fibro-test* or fibrometer or fibroscan or fib4 or fib-4):ti,ab #14 ((nafld or bard or ferritin* or fibrosis) near/4 (test* measure* or level* or ratio or score*)):ti,ab #15 ((glutamic-pyruvic transaminase or glutamic-oxaloacetic transaminase or sgot or sgpt or alt or ast) near/4 (test* or measure* or level* or ratio or score*)):ti,ab #16 (aspartate near/2 (aminotransferase or apoaminotransferase or transaminase) near/4 (test* or measure* or level* or ratio or score*)):ti,ab #17 (alanine near/2 (aminotransferase or transaminase) near/4 (test* or measure* or level* or ratio or score*)):ti,ab #18 ((ast-to-platelet raio index or apri or elf or enhanced liver fibrosis or nash) near/4 (test* or measure* or level* or score*)):ti,ab #19 ((biomarker* or marker*) near/4 (test* or measure* or level* or ratio or score*)):ti,ab #20 MeSH descriptor: [Magnetic Resonance Spectroscopy] explode all trees #21 MeSH descriptor: [Diffusion Magnetic Resonance Imaging] explode all trees
12 #22 (elastogra* or sonoelastogra* or elasticity imag* or sheer wave):ti,ab #23 (acoustic radiation force impulse or arfi):ti,ab #24 ((diffusion or weighted) near/2 (imag* or mri)):ti,ab #25 (mrs or ((nmr or magneetic or mr) near/2 spectroscop*)):ti,ab #26 {or #12-#25} #27 #10 and #26 #28 #5 and #27 Publication Year from 2015 to 2017 Science Index Expanded Steatosis 1 (TS=(fatty liver OR nonalcoholic fatty liver OR non-alcoholic fatty liver disease*)) AND LANGUAGE: (English) 2 (TS=((fatty OR fat or steato*)near(liver* or hepat*))) AND LANGUAGE: (English) 3 (TS=(steatohepat* OR (visceral NEAR steato*))) AND LANGUAGE: (English) 4 (TS=("NAFLD" OR NAFL* OR NASH)) AND LANGUAGE: (English) 5 (#4 OR #3 OR #2 OR #1) AND LANGUAGE: (English) 6 (DT=(conference* OR letter* OR editorial* OR news* or historical* OR comment* OR case*)) AND LANGUAGE: (English) 7 (TS=(RCT OR randomi$ed controlled trial)) AND LANGUAGE: (English) 8 (#6 NOT #7) AND LANGUAGE: (English) 9 (TS=(animal* or animal model* or animal experimentation OR rodentia OR animals laboratory)) AND LANGUAGE: (English) 10 (TI=(rat* or mouse or mice)) AND LANGUAGE: (English) 11 (TS=(animal* NOT human*)) AND LANGUAGE: (English) 12 #11 OR #10 OR #9 13 (#5 NOT #12) AND LANGUAGE: (English) 14 (TS=(alanine transaminase* OR ALT)) AND LANGUAGE: (English) 15 (TS=(aspartate aminotransferase* OR AST)) AND LANGUAGE: (English) 16 (TS=(gamma-glutamyltransferase* or gamma glutamyltransferase* or GGT)) AND LANGUAGE: (English)
13 17 (TS=(test* or measure* or level* or ratio*)) AND LANGUAGE: (English) 18 #16 OR #15 OR #14 19 #18 AND #17 20 (TS=(fatty liver ind* OR "fatty liver index" OR fli)) AND LANGUAGE: (English) 21 (TS=(steatotest OR steato test)) AND LANGUAGE: (English) 22 (TS=(liver fat scor*)) AND LANGUAGE: (English) 23 (TS=(ultrasonograph* OR ultrasound* OR sonograph* or echograph*)) AND LANGUAGE: (English) 24 (TS=(magnetic resonance imaging* OR magnetic resonance spectroscop* OR MRI OR MRS)) AND LANGUAGE: (English) 25 (TS=((controlled attenuation parameter NEAR "CAP") OR elasticity imaging technique*)) AND LANGUAGE: (English) 26 (#25 OR #24 OR #23 OR #22 OR #21 OR #20 OR #19) AND LANGUAGE: (English) 27 #26 AND #13 28 (TS=( sensitivity and specificity)) AND LANGUAGE: (English) 29 (TS=(predictive value* or ppv or npv or likelihood ra tio* or roc curve* or auc)) AND LANGUAGE: (English) 30 (TS=(diagnostic accuracy OR diagnostic test accuracy study)) AND LANGUAGE: (English) 31 (TS=(diagnos* NEAR (performance* OR accurac* or utilit* or value* or efficien* or effectiveness))) AND LANGUAGE: (English) 32 (TS=(biops* AND gold standard)) AND LANGUAGE: (English) 33 #32 OR #31 OR #30 OR #29 OR #28 34 #33 AND #27 Indexes=SCI-EXPANDED Timespan= Fibrosis 1 (TS=(fatty liver OR nonalcoholic fatty liver OR non-alcoholic fatty liver disease*)) AND LANGUAGE: (English) 2 (TS=((fatty OR fat or steato*)near(liver* or hepat*))) AND LANGUAGE: (English) 3 (TS=(steatohepat* OR (visceral NEAR steato*))) AND LANGUAGE: (English) 4 (TS=("NAFLD" OR NAFL* OR NASH)) AND LANGUAGE: (English) 5 (#4 OR #3 OR #2 OR #1) AND LANGUAGE: (English)
14 6 (DT=(conference* OR letter* OR editorial* OR news* or historical* OR comment* OR case*)) AND LANGUAGE: (English) 7 (TS=(RCT OR randomi$ed controlled trial)) AND LANGUAGE: (English) 8 (#6 NOT #7) AND LANGUAGE: (English) 9 (TS=(animal* or animal model* or animal experimentation OR rodentia OR animals laboratory)) AND LANGUAGE: (English) 10 (TI=(rat* or mouse or mice)) AND LANGUAGE: (English) 11 (TS=(animal* NOT human*)) AND LANGUAGE: (English) 12 #11 OR #10 OR #9 13 (#5 NOT #12) AND LANGUAGE: (English) 14 (TS=(alanine transaminase* OR ALT)) AND LANGUAGE: (English) 15 (TS=(aspartate aminotransferase* OR AST)) AND LANGUAGE: (English) 16 TS=(gamma-glutamyltransferase* or gamma glutamyltransferase* or GGT or keratin?18 or ferritin or biological marker* or biomarker*) 17 TS=(test* or measure* or level* or ratio* or diagnos*) 18 #16 OR #15 OR #14 19 #18 AND #17 20 TS=((fibro test* or fibro-test* or fibrometer or fibroscan or fib4 or fib-4 or glutamic-pyruvic transaminase or glutamic-oxaloacetic transaminase or sgot or sgpt or nafld or bard or ferritin* or fibrosis or ast-to-platelet ratio OR apri or elf or "enhanced liver fibrosis" or nash or biomarker* or marker*) AND (test* or measure* or level* or ratio or score* or index)) 21 TS=((aspartate OR alanine) AND (aminotransferase OR apoaminotransferase or transaminase) AND (test* or level* or measure* or ratio or score*)) 22 TS=(magnetic resonance spectroscop* OR MRS OR "magnetic resonance imaging" OR MRI) 23 TS=(ultrasonograph* OR ultrasound* OR sonograph* or echograph* OR sonoelastogra* or elasticity imag* or "sheer wave" or acoustic radiation force impulse OR arfi) 24 TS=((diffusion or weighted) AND (imag* or mri)) 25 TS=(MRS OR (NMR or magnetic or mr)near spectroscop*) 26 (#25 OR #24 OR #23 OR #22 OR #21 OR #20 OR #19) AND LANGUAGE: (English) 27 #26 AND #13 28 (TS=( sensitivity and specificity)) AND LANGUAGE: (English)
15 29 (TS=(predictive value* or ppv or npv or likelihood ra tio* or roc curve* or auc)) AND LANGUAGE: (English) 30 (TS=(diagnostic accuracy OR diagnostic test accuracy study)) AND LANGUAGE: (English) 31 (TS=(diagnos* NEAR (performance* OR accurac* or utilit* or value* or efficien* or effectiveness))) AND LANGUAGE: (English) 32 (TS=(biops* AND gold standard)) AND LANGUAGE: (English) 33 #32 OR #31 OR #30 OR #29 OR #28 34 #33 AND #27 Indexes=SCI-EXPANDED Timespan=
The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis
The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis Objectives: Liver biopsy is the gold standard for diagnosing the extent of fibrosis in NAFLD/NASH;
More informationIn Search of New Biomarkers for Nonalcoholic Fatty Liver Disease
REVIEW In Search of New Biomarkers for Nonalcoholic Fatty Liver Disease Ting-Ting Chan, M.R.C.P., and Vincent Wai-Sun Wong, M.D. Nonalcoholic fatty liver disease (NAFLD) affects 15% to 40% of the general
More informationDiagnostic Challenges of Nonalcoholic Fatty Liver Disease/ Nonalcoholic Steatohepatitis
REVIEW Diagnostic Challenges of Nonalcoholic Fatty Liver Disease/ Nonalcoholic Steatohepatitis Erin Cleveland, M.D.,* Andrew Bandy, M.D., and Lisa B. VanWagner, M.D., M.Sc. *, Nonalcoholic fatty liver
More informationNoninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease
Noninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease Policy Number: 2.04.41 Last Review: 2/2019 Origination: 2/2017 Next Review: 2/2020 Policy Blue Cross and
More informationCerebral palsy in under 25s: assessment and management
National Institute for Health and Care Excellence Final Version Cerebral palsy in under 25s: assessment and management Appendix E Search Strategies NICE Guideline NG62 Methods, evidence and recommendations
More informationAppendix F: Literature search strategies
Appendix F: Contents Introduction Section F.1 F.1.1 F.1.2 F.1.3 F.1.4 F.1.5 F.1.6 Section F.2 Section F.3 F.3.1 F.3.2 F.3.3 F.3.4 F.3.5 F.3.6 Section F.4 F.4.1 F.4.2 Search methodology Study filter terms
More informationRenal and ureteric stones: assessment and management
National Institute for Health and Care Excellence Consultation Renal and ureteric stones: assessment and management Metabolic investigations NICE guideline Intervention evidence review July 08 Consultation
More informationPractical Diagnosis and Staging of Nonalcoholic Fatty Liver Disease: A Narrative Review
Practical Diagnosis and Staging of Nonalcoholic Fatty Liver Disease: A Narrative Review Authors: Jennifer Gallacher, 1 *Stuart McPherson 1,2 1. Liver Unit, Newcastle Upon Tyne Hospitals NHS Trust, Freeman
More informationNoninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease
Noninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease Policy Number: 2.04.41 Last Review: 2/2018 Origination: 2/2017 Next Review: 2/2019 Policy Blue Cross and
More informationMP Noninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease
Medical Policy BCBSA Ref. Policy: 2.04.41 Last Review: 11/15/2018 Effective Date: 11/15/2018 Section: Medicine Related Policies 9.01.502 Experimental / Investigational Services DISCLAIMER Our medical policies
More informationUpdate on Non-Alcoholic Fatty Liver Disease. Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI
Update on Non-Alcoholic Fatty Liver Disease Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI February 3, 2018 Disclosure Clinical trials: Genfit Speaker s Bureau: none
More informationNoninvasive Diagnosis and Staging of Liver Disease. Naveen Gara, MD
Noninvasive Diagnosis and Staging of Liver Disease Naveen Gara, MD Outline Brief overview of the anatomy of liver Liver-related lab tests Chronic liver disease progression Estimation of liver fibrosis
More informationRenal and ureteric stones: assessment and management
National Institute for Health and Care Excellence Final Renal and ureteric stones: assessment and management Metabolic investigations NICE guideline NG118 Intervention evidence review (A) January 2019
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Noninvasive Techniques for the Evaluation and Monitoring of Page 1 of 38 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Noninvasive Techniques for the Evaluation
More informationPreoperative tests (update)
. Preoperative tests (update) Routine preoperative tests for elective surgery NICE guideline NG45 Appendix G: April 2016 Developed by the National Guideline Centre, hosted by the Royal College of Physicians.
More informationThe role of ARFI and APRI in diagnosis of liver fibrosis on patients with common chronic liver diseases
RESEARCH ARTICLE The role of ARFI and APRI in diagnosis of liver fibrosis on patients with common chronic liver diseases Objective: This study aimed to investigate the value of liver fibrosis assessment
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Noninvasive Techniques for the Evaluation and Page 1 of 34 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Noninvasive Techniques for the Evaluation and Professional
More informationNASH : Diagnosis and investigation. VII Workshop international, Curitiba, Brazil 29/08/2014
NASH : Diagnosis and investigation VII Workshop international, Curitiba, Brazil 29/08/2014 Vlad Ratziu, Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière, Paris, France Usual diagnostic circumstances
More informationNonalcoholic Fatty Liver Disease: Definitions, Risk Factors, and Workup
REVIEW REVIEW Nonalcoholic Fatty Liver Disease: Definitions, Risk Factors, and Workup Puneet Puri, M.B.B.S., M.D. and Arun J. Sanyal, M.B.B.S., M.D. Nonalcoholic fatty liver disease (NAFLD) is defined
More informationNAFLD and NASH: The Not-So-New Kids on the Block
NAFLD and NASH: The Not-So-New Kids on the Block Mary E. Rinella, MD Associate Professor of Medicine Feinberg School of Medicine Northwestern University Chicago, Illinois This program is supported by an
More informationIS LIVER BIOPSY NECESSARY IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE?
Rev. Med. Chir. Soc. Med. Nat., Iaşi 2016 vol. 120, no. 3 INTERNAL MEDICINE - PEDIATRICS UPDATES IS LIVER BIOPSY NECESSARY IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE? R. S. Gavril 1, Laura Mihalache
More informationBilag 5. Søgestreng sekundær og primær litteratur
Bilag 5. Søgestreng sekundær og primær litteratur Søgespecialister Conni Skrubbeltrang og Jette Frost Jepsen Det Nationale Sorgcenter Database Udbyder Resultat Dato Medline Ovid 61 26.06.2017 Embase Ovid
More informationNAFLD: evidence-based management. Curso de residentes AEEH Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain
NAFLD: evidence-based management Curso de residentes AEEH 2017 Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain Clinical case - 55 yo female - Sent for incidental steatosis at abdominal
More informationNovel multiparametric magnetic resonance elastography (MRE) protocol accurately predicts NAS score for NASH diagnosis
Novel multiparametric magnetic resonance elastography (MRE) protocol accurately predicts NAS score for NASH diagnosis Alina M. Allen, Meng Yin, Sudhakar K. Venkatesh, Taofic Mounajjed, Todd A. Kellogg,
More informationNHSScotland is required to consider the Scottish Health Technologies Group (SHTG) advice.
Advice Statement 010-18 July 2018 Advice Statement What is the most accurate and cost-effective direct test (ELF test, hyaluronic acid, P3NP, Fibroscan or ARFI elastography) for detecting and staging liver
More informationNon-Invasive Testing for Liver Fibrosis
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Non-Invasive Testing for Liver Fibrosis John Scott, MD, MSc Associate Professor, University of Washington Associate Clinic Director, Hep/Liver Clinic, Harborview
More informationPage: 1 of 19. Noninvasive Techniques for the Evaluation and Monitoring of Patients with Chronic Liver Disease
and Monitoring of Patients with Chronic Liver Page: 1 of 19 Last Review Status/Date: March 2015 and Monitoring of Patients with Chronic Liver Description Options for noninvasive monitoring of liver fibrosis
More informationImproved Hepatic Fibrosis Grading Using Point Shear Wave Elastography and Machine Learning
Improved Hepatic Fibrosis Grading Using Point Shear Wave Elastography and Machine Learning Presenter: Hersh Sagreiya 1, M.D. Authors: Alireza Akhbardeh 1, Ph.D., Isabelle Durot 1, M.D., Carlo Filice 2,
More informationLiver Fat Quantification
Liver Fat Quantification Jie Deng, PhD, DABMP Department of Medical Imaging May 18 th, 2017 Disclosure Research agreement with Siemens Medical Solutions 2 Background Non-alcoholic fatty liver diseases
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Harris R, Harman DJ, Card TR, Aithal GP, Guha
More informationNONINVASIVE TECHNIQUES FOR EVALUATION AND MONITORING OF CHRONIC LIVER DISEASE
LIVER DISEASE Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are
More informationMedical Policy Non-invasive Tests for Hepatic Fibrosis
Medical Policy Non-invasive Tests for Hepatic Fibrosis Subject: Non-invasive Tests for Hepatic Fibrosis Background: Accurately diagnosing liver fibrosis and inflammatory activity are the most important
More informationNONINVASIVE IMAGING METHODS FOR ASSESSMENT OF LIVER DAMAGE IN NASH
NONINVASIVE IMAGING METHODS FOR ASSESSMENT OF LIVER DAMAGE IN NASH Bachir Taouli, MD Director of Body MRI and Cancer Imaging Program Department of Radiology / Translational and Molecular Imaging Institute
More informationMonitoring Hepatitis C
Monitoring Hepatitis C Section Six Monitoring Hepatitis C Screening for hepatitis C is not routinely done, so you may have to request a test from your medical provider. This usually involves an antibody
More informationNational Horizon Scanning Centre. Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis. June 2008
Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis June 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationNon-alcoholic fatty liver disease
Non-alcoholic fatty liver disease Link to this article online for CPD/CME credits Naveed Sattar, 1 Ewan Forrest, 2 David Preiss 1 1 BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow
More informationSimple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease
1 Liver Unit, Newcastle Upon Tyne Hospitals NHS Trust, Freeman Hospital, Newcastle upon Tyne, UK 2 Institute of Cellular Medicine, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne,
More informationThe Belgian Association for Study of the Liver Guidance Document on the Management of Adult and Paediatric Non-Alcoholic Fatty Liver Disease
POSITION STATEMENT 1 The Belgian Association for Study of the Liver Guidance Document on the Management of Adult and Paediatric Non-Alcoholic Fatty Liver Disease S. Francque 1,2, N. Lanthier 3, L. Verbeke
More informationAssessment of Liver Stiffness by Transient Elastography in Diabetics with Fatty Liver A Single Center Cross Sectional observational Study
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 6 Ver. IV (June. 2017), PP 49-53 www.iosrjournals.org Assessment of Liver Stiffness by Transient
More informationLiterature search strategies
Literature search strategies A.1.1 Contents Introduction Section A.1.2 Section A.1.3 A.1.3.1 A.1.3.2 A.1.3.3 A.1.3.4 A.1.3.5 A.1.3.6 A.1.3.7 Section A.1.4 A.1.4.1 A.1.4.2 A.1.4.3 A.1.4.4 A.1.4.5 A.1.4.6
More informationLiver elastography ultrasound cpt code
Liver elastography ultrasound cpt code In a multi-center study, Barbero-Villares et al (2012) evaluated the presence of significant liver fibrosis by transient elastography (FibroScan) in inflammatory.
More informationUrinary incontinence and pelvic organ prolapse in women: management
National Institute for Health and Care Excellence Final Urinary incontinence and pelvic organ prolapse in women: management [G] Evidence review for assessing pelvic organ prolapse NICE guideline NG123
More informationWhat is NAFLD?.NASH? Presenter Disclosure Information. Learning Objectives. Case 1: Rob. Questions Pertinent to Rob
Presenter Disclosure Information 5 6pm Nonalcoholic Fatty Liver Disease (NAFLD): Another Obesity-Related Epidemic SPEAKER Elliot Tapper, MD The following relationships exist related to this presentation:
More informationNon-invasive diagnostic biomarkers
Non-invasive diagnostic biomarkers Liver Forum, November 12 th, 2015 Rohit Loomba, MD, MHSc Professor of Medicine (with tenure) Director, NAFLD Research Center, Division of Gastroenterology, Department
More informationPreliminary clinical experience with Shear Wave Dispersion Imaging for liver viscosity
Preliminary clinical experience with Shear Wave Dispersion Imaging for liver viscosity Dr. Katsutoshi Sugimoto Department of Gastroenterology and Hepatology, Tokyo Medical University, Japan Introduction
More informationIn response to an enquiry from the Scottish Clinical Biochemistry Managed Diagnostic Network
Evidence Note Number 82 July 2018 In response to an enquiry from the Scottish Clinical Biochemistry Managed Diagnostic Network What is the most accurate and cost-effective direct test (ELF test, hyaluronic
More informationABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust
ABNORMAL LIVER FUNCTION TESTS Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust INTRODUCTION Liver function tests Cases Non invasive fibrosis measurement Questions UK MORTALITY RATE
More informationNon-Alcoholic Steatohepatitis (NASH): What the Gastroenterologist Should Know
Non-Alcoholic Steatohepatitis (NASH): What the Gastroenterologist Should Know Naga P. Chalasani, MD, FACG Professor of Medicine and Cellular & Integrative Physiology Director, Division of GI and Hepatology
More informationPretreatment Evaluation
Pretreatment Evaluation Objective At the end of this lecture, the learner will be able to: Outline the appropriate evaluation of a person infected with HCV in order to assess the benefits and risks of
More informationBio Predictive. FibroTest/FibroSure Scientific Publications. Houot 2015 FibroTest, TE, FIB-4, APRI Meta-analysis
AASLD 2015 /FibroSure Scientific Publications Section 1 - compared to APRI, FIB-4 and transient elastography Houot 2015, TE, FIB-4, APRI Meta-analysis is superior to TE by Fibroscan, APRI and Fib-4 using
More informationAbstract. Introduction
Med. J. Cairo Univ., Vol. 82, No. 2, September: 185-194, 2014 www.medicaljournalofcairouniversity.net Performance of Acoustic Radiation Force Impulse Imaging in Staging Liver Fibrosis and Cirrhosis in
More informationWhen to Treat: Staging Liver Disease David L. Thomas, MD, MPH
When to Treat: Staging Liver Disease David L. Thomas, MD, MPH Professor of Medicine Johns Hopkins School of Medicine Disclosures Received royalties from UpToDate, Inc. Staging refers to the assessment
More informationClinical Policy Title: Liver elastography
Clinical Policy Title: Liver elastography Clinical Policy Number: CCP.1118 Effective Date: October 1, 2014 Initial Review Date: June 18, 2014 Most Recent Review Date: August 7, 2018 Next Review Date: August
More informationFaculty Disclosure. Objectives. Cirrhosis Management for the Family Physician 18/11/2014
Cirrhosis Management for the Family Physician Mang Ma, MD, FRCP Professor University of Alberta Faculty: Mang Ma Faculty Disclosure Relationships with commercial interests: Advisory Board: Merck, Gilead
More information2 nd International Workshop on NASH Biomarkers, Washington DC, May 5-6, 2017
Hepatic Proton Density Fat Fraction Correlates With Histologic Measures of Steatosis and Is Responsive to Changes in Those Measures in a Multi-center Nonalcoholic Steatohepatitis Clinical Trial Michael
More informationBio Predictive. FibroTest Scientific Publications. Ratziu 2016 FibroMax NASH. Friedman 2016 FibroTest NASH EASL Key Publications for 2017
EASL 2017 Scientific Publications Ratziu 2016 NASH Friedman 2016 NASH SteatoTest and sensitive markers of improvement in NASH trial using Elafibranor Elafibranor, an agonist of the peroxisome proliferator
More informationRelationship between Controlled Attenuation Parameter and Hepatic Steatosis as Assessed by Ultrasound in Alcoholic or Nonalcoholic Fatty Liver Disease
Gut and Liver, Vol. 10, No. 2, March 2016, pp. 295-302 ORiginal Article Relationship between Controlled Attenuation Parameter and Hepatic Steatosis as Assessed by Ultrasound in Alcoholic or Nonalcoholic
More informationThe classical metabolic work-up, approved by the Ethics Committee of the Antwerp
SUPPLEMENTARY MATERIALS METHODS Metabolic work-up The classical metabolic work-up, approved by the Ethics Committee of the Antwerp University Hospital and requiring written informed consent, included a
More informationPretreatment Evaluation
Pretreatment Evaluation Disclosures Research supported by Gilead Sciences Inc.: Site investigator for HIV/HCV SWITCH Registry Study Key personnel for FOCUS HCV Screening Program through Vanderbilt University
More informationPROPOSTA DI UN NUOVO ALGORIMO PER LA DIAGNOSI ECOGRAFICA DELLE MALATTIE CRONICHE DEL FEGATO
PROPOSTA DI UN NUOVO ALGORIMO PER LA DIAGNOSI ECOGRAFICA DELLE MALATTIE CRONICHE DEL FEGATO A. Giorgio Direttore del servizio di Ecografia Interventistica Istituto Clinico S.Rita -IRCCS -Atripalda (Avellino)
More informationSection: Laboratory Last Reviewed Date: June Policy No: 47 Effective Date: August 1, 2013
Medical Policy Manual Topic: Multianalyte Assays with Algorithmic Analysis for the Evaluation and Monitoring of Patients with Chronic Liver Disease Date of Origin: June 2013 Section: Laboratory Last Reviewed
More information/ FIB4 Index , simple steatosis. FIB4 Index. FIB4 Index. FIB4 Index FIB4 Index. Sterling FIB4 Index. FIB4 Index AST AST ALT
原 著 29 34-41, 2014 FIB4 Index 1 1 1 1 2 1 1 FIB4 Index FIB4 Index cut off 2.67 2.67 12,059 FIB4 IndexFIB4 Index 2.67 / FIB4 Index AST ALT FIB4 Index 2.67 161 1.3% FIB4 Index 5 FIB4 Index 1.1 5 1.6 FIB4
More informationNonalcoholic fatty liver disease (NAFLD) and nonalcoholic. Noninvasive Assessment of Nonalcoholic Fatty Liver Disease in Obese or Overweight Patients
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012;10:1162 1168 Noninvasive Assessment of Nonalcoholic Fatty Liver Disease in Obese or Overweight Patients SVEN M. A. FRANCQUE,* AN VERRIJKEN, ILSE MERTENS, GUY
More informationNash with cirrhosis icd 10
Free, official coding info for 2018 ICD-10-CM K75.81 - includes detailed crosswalks, DRG grouping and more. Free, official coding info for 2018 ICD-10-CM K74.69 - includes detailed crosswalks, DRG grouping
More informationNAFLD & NASH. Naga Chalasani, MD, FACG Professor of Medicine and Cellular & Integrative Physiology Director, Division of GI and Hepatology
NAFLD & NASH Naga Chalasani, MD, FACG Professor of Medicine and Cellular & Integrative Physiology Director, Division of GI and Hepatology Indiana University School of Medicine ACG Midwest Regional Course,
More informationUnderstanding your FibroScan Results
PATIENT & CAREGIVER EDUCATION Understanding your FibroScan Results This information will help you understand your FibroScan results. About FibroScan FibroScan is a specialized ultrasound machine for your
More informationNon-Invasive Assessment of Liver Fibrosis. Patricia Slev, PhD University of Utah Department of Pathology
Non-Invasive Assessment of Liver Fibrosis Patricia Slev, PhD University of Utah Department of Pathology Disclosure Patricia Slev has no relevant financial relationships to disclose. 2 Chronic Liver Disease
More informationEvaluation of liver and spleen stiffness using a ultrasound guided method: Accuracy of ARFI(R) measurements in liver disease patients
Evaluation of liver and spleen stiffness using a ultrasound guided method: Accuracy of ARFI(R) measurements in liver disease patients Poster No.: C-3242 Congress: ECR 2010 Type: Topic: Authors: Keywords:
More informationNon-Alcoholic Fatty Liver Diseasean underestimated epidemic
Non-Alcoholic Fatty Liver Diseasean underestimated epidemic Amir Shlomai MD,PhD Head, Department of Medicine D The Liver Institute Rabin Medical Center, Beilinson Hospital The IASLD semi-annual meeting-
More informationFour search strategies used- COPD, bronchiectasis, restrictive lung disease, and asthma.
b) Web appendix: Literature Search details Sources to be searched for the guidelines; Reviews (CDSR) Database of Abstracts of Reviews of Effects (DARE) Dates searched: 1980 onwards All study types English
More informationNon-invasive diagnosis of hepatitis B virus-related cirrhosis
Online Submissions: http://www.wjgnet.com/esps/ bpgoffice@wjgnet.com doi:10.3748/wjg.v20.i2.445 World J Gastroenterol 2014 January 14; 20(2): 445-459 ISSN 1007-9327 (print) ISSN 2219-2840 (online) 2014
More informationNON INVASIVE EVALUATION OF DISEASE PROGRESSION IN CHRONIC LIVER DISEASES
Best of EASL -, Ethiopia 29 Sep to 01 Oct, 2016 Inaugural meeting of the Sub Saharan GI-Hepatology Working Group Incorporating Best of AGA and Best of EASL NON INVASIVE EVALUATION OF DISEASE PROGRESSION
More informationChewing the Fat on Fatty Liver Mike Kolber MD, CCFP, MSc PEIP 2018
Chewing the Fat on Fatty Liver Mike Kolber MD, CCFP, MSc PEIP 2018 Faculty/Presenter Disclosure Faculty: Michael Kolber Relationships with financial sponsors: Grants/Research Support: Alberta College of
More informationBackground of the FIB-4 Index in Japanese Non-Alcoholic Fatty Liver Disease
ORIGINAL ARTICLE Background of the FIB-4 Index in Japanese Non-Alcoholic Fatty Liver Disease Takashi Wada and Mikio Zeniya Abstract Objective We investigated the distribution and characteristics of the
More informationLiver 102: Injury and Healing
Liver 102: Injury and Healing Dawn Pease, MSN, RN, ANP-BC Brackenridge Specialty Clinics University Medical Center Brackenridge Austin, TX Seton Healthcare Family Liver 102 Outline Biochemical patterns
More informationLFTs: an update A MacGilchrist PLIG meeting 31st January 2019
LFTs: an update A MacGilchrist PLIG meeting 31 st January 2019 LFTs: what are we trying to achieve? (1) The case against investigation abnormal LFTs in up to 21% of the population only 1-2% develop significant
More informationDietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and
Dietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and Dietetics Tehran University of Medical Sciences Honorary Academic
More informationNon-Alcoholic Fatty Liver Disease
Non-Alcoholic Fatty Liver Disease Varun Saxena, MD MAS Gastroenterology and Hepatology Kaiser Permanente South San Francisco Assistant Clinical Professor University of California San Francisco January
More informationA study of effect of alcohol on liver function tests (LFT) in Garhwal hills, India
International Journal of Research in Medical Sciences Gogoi JB et al. Int J Res Med Sci. 2018 Jan;6(1):94-98 www.msjonline.org pissn 2320-6071 eissn 2320-6012 Original Research Article DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20175536
More informationHEP DART 2017, Kona, Hawaii
HEP DART 2017, Kona, Hawaii Rong Yu 1, Ke Xu 1, Jing Li 1, Tong Sun 1, Shengjiang Zhang 2, Jinhua Shao 2, Jin Sun 2, Qiong He 3, Jianwen Luo 3, Cheng Wang 4, Yudong Wang 4, Jing Chen 4, Vanessa Wu 4, George
More information*APHP: Hôpital Beaujon Professor P Bedossa, Dr F Degos, Professor P Marcellin, Professor
APPENDIX 1 LIST OF COINVESTIGATORS *APHP: Hôpital Beaujon Professor P Bedossa, Dr F Degos, Professor P Marcellin, Professor M Vidaud; Hôpital Cochin-Necker: Professor S Pol, Professor Ph Sogni, Professor
More informationUNIVERSA MEDICINA. Forns index as a useful noninvasive predictor of esophageal varices in liver cirrhosis
UNIVERSA MEDICINA September-December, 2016 Vol.35 - No.3 Forns index as a useful noninvasive predictor of esophageal varices in liver cirrhosis Rizqi Arini Siregar*, Leonardo B. Dairi*, and Gontar Alamsyah
More informationULTRASOUND IN CHRONIC LIVER DISEASE
ULTRASOUND IN CHRONIC LIVER DISEASE Prof. Ioan Sporea, MD, PhD Head of Department of Gastroenterology and Hepatology University of Medicine and Pharmacy, Timişoara, Romania WFUMB Center of Education (COE),
More informationNAFLD AND TYPE 2 DIABETES
NAFLD AND TYPE 2 DIABETES Sonia Caprio, MD STOPNASH Symposium on the Origin and Pathways of Nonalcoholic Steatohepatitis Washington 7, 215 Global Projection of Diabetes Hossain P et al. N Engl J Med 27;356:213
More informationEvaluating Obese Persons With Abnormal Liver Chemistries
Mary E. Rinella, MD, FAASLD Evaluating Obese Persons With Abnormal Liver Chemistries Postgraduate Course: Challenges in Management of Common Liver Diseases 275 1 25 year old obese Hispanic man with obesity,
More informationAppendix 1. Search strategies for individual databases
Appendix 1. Search strategies for individual databases OVID Database: Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R)
More informationInvestigating and Referring Incidental Findings of Abnormal Liver Tests
Investigating and Referring Incidental Findings of Abnormal Liver Tests Note on Referral Guidelines: these revised guidelines are presented as a tool to aid appropriate referral and management of common
More informationPrevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus patients in a tertiary care hospital of Bihar
Original Research Article Prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus patients in a tertiary care hospital of Bihar Naresh Kumar 1, Jyoti Kumar Dinkar 2*, Chandrakishore
More informationEvaluation of liver and spleen stiffness using a ultrasound guided method: Accuracy of ARFI(R) measurements in liver disease patients
Evaluation of liver and spleen stiffness using a ultrasound guided method: Accuracy of ARFI(R) measurements in liver disease patients Poster No.: C-3242 Congress: ECR 2010 Type: Topic: Authors: Keywords:
More informationPretreatment Evaluation
Pretreatment Evaluation Disclosures Research supported by Gilead Sciences Inc.: Site investigator for HIV/HCV SWITCH Registry Study Key personnel for FOCUS HCV Screening Program through Vanderbilt University
More informationMultianalyte assays with algorithmic analyses are considered investigational for the diagnosis or monitoring of patients with chronic liver disease.
2.04.41 Multianalyte Assays with Algorithmic Analysis for the Evaluation and Monitoring of Patients with Chronic Liver Disease Section 2.0 Medicine Subsection 2.04 Pathology/Laboratory Effective Date September
More informationDISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea
DISCLOSURES This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea Cardea Services is approved as a provider of continuing nursing education by Montana Nurses Association,
More informationM30 Apoptosense ELISA. A biomarker assay for detection and screening of NASH
M30 Apoptosense ELISA A biomarker assay for detection and screening of NASH NASH A Global Disease In the Western countries, Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common liver disease, strongly
More informationORIGINAL ARTICLE. Both these authors contributed equally to this study. Liver International ISSN
Liver International ISSN 1478-3223 ORIGINAL ARTICLE The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients
More informationIEHP UM Subcommittee Approved Authorization Guidelines Liver Biopsy in Conjunction with Bariatric Surgery
Policy: IEHP does not cover routine liver biopsy in conjunction with bariatric surgery due to insufficient evidence that such practice alters the clinical management of non-alcoholic fatty liver disease
More informationNational Horizon Scanning Centre. Transient elastography (FibroScan) for evaluating liver fibrosis. April 2008
Transient elastography (FibroScan) for evaluating liver fibrosis April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationLa Steatosi epatica nel paziente con infezione da HIV
La Steatosi epatica nel paziente con infezione da HIV Dott. Nicola Squillace Clinica delle Malattie infettive ASST-Monza, Ospedale San Gerardo-Università di Milano-Bicocca Introduction/Background Definition
More informationReview Article Noninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease
International Journal of Endocrinology Volume 2015, Article ID 343828, 9 pages http://dx.doi.org/10.1155/2015/343828 Review Article Noninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty
More informationDiabetes Liver Screen
YOUR LIVER AND YOUR HEALTH Diabetes Liver Screen Non-Alcoholic Fatty Liver Disease (NAFLD) PROF. SUZANNE NORRIS www.liverwellness.ie The spectrum of non-alcoholic fatty liver disease Diabetes Liver Screen
More information